BioSpace News Archive

Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the six months ended June 30, 2020 . During the reporting period, Ascentage Pharma m

Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic® FFPE to Pure RNA Kit.

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II human trial to treat inflammation in patients with severe complications from Covid-19

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Genosity Inc., announced today that it has received CLIA approval for its tumor exome and liquid biopsy cancer monitoring platform, AsTra (Assessment and Tracking), designed to identify a patient’s unique tumor molecular profile that can be used for ongoing, personalized Minimal Residual Disease (MRD) monitoring.

SQI Diagnostics, Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the Company’s board of directors has appointed Robert L. Chioini as Chief Executive Officer

Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates

SkyWater Technology, the trusted technology realization partner, announced the DARPA Three Dimensional Monolithic System-on-a-Chip (3DSoC) program, in collaboration with Massachusetts Institute of Technology (MIT), has entered its second phase

Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office has granted a patent on use and methods of treatment of Crohn’s disease with Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies.